Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Blood advances - 6(2022), 19 vom: 11. Okt., Seite 5550-5555 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Savage, Kerry J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.10.2022 Date Revised 16.11.2022 published: Print ClinicalTrials.gov: NCT01777152 Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2020003971 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339994282 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339994282 | ||
| 003 | DE-627 | ||
| 005 | 20231226004138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2020003971 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM339994282 | ||
| 035 | |a (NLM)35470385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Savage, Kerry J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2022 | ||
| 500 | |a Date Revised 16.11.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT01777152 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Ki-1 Antigen |2 NLM | |
| 650 | 7 | |a Vincristine |2 NLM | |
| 650 | 7 | |a 5J49Q6B70F |2 NLM | |
| 650 | 7 | |a Brentuximab Vedotin |2 NLM | |
| 650 | 7 | |a 7XL5ISS668 |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Horwitz, Steven M |e verfasserin |4 aut | |
| 700 | 1 | |a Advani, Ranjana |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Jacob Haaber |e verfasserin |4 aut | |
| 700 | 1 | |a Domingo-Domenech, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Morschhauser, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Alpdogan, Onder |e verfasserin |4 aut | |
| 700 | 1 | |a Suh, Cheolwon |e verfasserin |4 aut | |
| 700 | 1 | |a Tobinai, Kensei |e verfasserin |4 aut | |
| 700 | 1 | |a Shustov, Andrei |e verfasserin |4 aut | |
| 700 | 1 | |a Trneny, Marek |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Zinzani, Pier Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Trümper, Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Ilidge, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connor, Owen A |e verfasserin |4 aut | |
| 700 | 1 | |a Pro, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Harry |e verfasserin |4 aut | |
| 700 | 1 | |a Bunn, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Fenton, Keenan |e verfasserin |4 aut | |
| 700 | 1 | |a Fanale, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Puhlmann, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Iyer, Swaminathan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 6(2022), 19 vom: 11. Okt., Seite 5550-5555 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2022 |g number:19 |g day:11 |g month:10 |g pages:5550-5555 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2020003971 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2022 |e 19 |b 11 |c 10 |h 5550-5555 | ||